# Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

> **NCT03048578** · PHASE4 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 132 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Saxenda
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03048578
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-22
- **Primary completion:** 2021-03-02
- **Final completion:** 2021-03-02
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2022-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03048578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03048578, "Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03048578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*